20,917 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Teza Capital Management LLC

Teza Capital Management LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,917 shares of the biopharmaceutical company's stock, valued at approximately $437,000.

Several other large investors have also bought and sold shares of the stock. Summit Investment Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 5.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 580 shares during the last quarter. Bank of Montreal Can grew its position in Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 875 shares in the last quarter. Rhumbline Advisers increased its stake in Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after buying an additional 952 shares during the last quarter. Handelsbanken Fonder AB increased its stake in Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after buying an additional 1,000 shares during the last quarter. Finally, PDT Partners LLC lifted its position in shares of Catalyst Pharmaceuticals by 5.2% during the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock worth $431,000 after buying an additional 1,030 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird boosted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This represents a 38.98% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 351,879 shares of company stock worth $8,214,815. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:CPRX opened at $24.63 on Tuesday. The firm has a market capitalization of $3.00 billion, a PE ratio of 20.87, a P/E/G ratio of 3.31 and a beta of 0.70. The company has a 50-day moving average price of $23.30 and a two-hundred day moving average price of $22.50. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.75 and a twelve month high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.